Inside the Downey Modulation Study, and Its Limits
Medically reviewed by
4 independent reviewers
Andrew Conrad Barile, PT, DPT
Doctor of Physical Therapy (DPT) | Licensed Physical Therapist (PT) | CEO and Founder, Xtreem Pulse LLC
Read bio
Dr. Andrew Conrad Barile is a Doctor of Physical Therapy and the CEO and Founder of Xtreem Pulse LLC, the engineering company behind PureLift. He earned his Doctorate in Physical Therapy from Daemen College and is a licensed physical therapist.
He brings over two decades of clinical and entrepreneurial experience across physical therapy, craniosacral therapy and medical device innovation, built on a working knowledge of human anatomy and muscle physiology.
For PureLift LAB he reviews how current is delivered across all ten levels, from sub-sensory nanocurrent and skin-level microcurrent to motor-level EMS, and how the Infuse pass fits into the same ten-minute routine.
Bertica M. Rubio, M.D.
Board-Certified Physician, Dartmouth Medical School | Medical Director, Antiaging Regenerative Medicine Clinic
Read bio
Dr. Bertica M. Rubio is a board-certified physician and Medical Director of the Antiaging Regenerative Medicine Clinic in Redlands, California. She earned her Doctor of Medicine from Dartmouth Medical School and completed her pediatrics residency at UC Irvine Medical Center.
With decades of clinical experience, she specialises in age management medicine, regenerative medicine, wound healing and growth factor therapies, and her practice integrates evidence-based medical science with advanced aesthetic treatment.
For PureLift LAB she reviews articles for medical accuracy across the whole dial, from the gentle nanocurrent and microcurrent settings through to muscle-level EMS and the Infuse pass.
Daniel Grinberg, MD, FACS
Board-Certified Otolaryngologist | Head and Neck Surgeon | Fellow, American College of Surgeons | Mount Sinai
Read bio
Daniel Grinberg, MD, FACS is a board-certified otolaryngologist and head and neck surgeon at ENT and Allergy Associates in West Nyack, New York. He earned his medical degree from Columbia University College of Physicians and Surgeons.
He completed his otolaryngology residency at New York University Medical Center, serves as Assistant Clinical Professor at Mount Sinai School of Medicine, and is a Fellow of both the American College of Surgeons and the American Academy of Otolaryngology.
For PureLift LAB he brings a wider clinical lens, connecting at-home facial stimulation from microcurrent to EMS to the anatomy underneath, with the same rigour we apply to every device specification.
Prof. Dr. med. Ivo Buschmann
Chair of Angiology, Medizinische Hochschule Brandenburg | Clinic Director, University Clinic for Angiology
Read bio
Prof. Dr. med. Ivo Buschmann is Chair of Angiology at the Medizinische Hochschule Brandenburg Theodor Fontane and Clinic Director of the University Clinic for Angiology at the Brandenburg University Hospital.
He trained at the University of Hamburg, was a Max Planck Society Fellow at the Max Planck Institute for Heart and Lung Research, and held senior consultant posts at the Charite Universitatsmedizin Berlin before his appointment as Chair in 2016.
One of Europe's leading authorities on arteriogenesis, with over 150 peer-reviewed publications and US and EU patents, he reviews for PureLift LAB how the evidence on electrical stimulation is read and where its limits lie.
Share
Downey and colleagues, 2011, is the paper most often cited when any brand in this category talks about varied frequency, including us.
This article covers what actually decides the answer, such as:
- What the study looked at
- What it legitimately supports
- What it cannot support
- The paper that found otherwise
- Why this page exists
and many more!
Here is what it tested, what it can support, and the paper that reached a different conclusion.
Key Points:
It tested a modulation strategy in a neuromuscular electrical stimulation protocol, not a facial one.
The finding supports frequency variation extending a defined performance endpoint against constant frequency.
It says nothing about wrinkles, contour, or any cosmetic outcome.
Papaiordanidou and colleagues report a case where modulation did not help.
A design principle is not a product claim, and the distinction is the whole point of this page.
What the study looked at
Downey and colleagues examined whether varying stimulation frequency, rather than holding it constant, changed how long a defined performance endpoint could be sustained under a neuromuscular electrical stimulation protocol (PMID 21996798).
The underlying question is accommodation: a nerve presented with an identical signal repeatedly responds less over time, while the current stays the same.
The hypothesis was that varying the signal keeps the response going longer, and the finding supported it under the conditions tested.
What it legitimately supports
That varied frequency is a reasonable engineering choice for a stimulation device, because the alternative accommodates faster.
That is a design rationale, and it is why PDM cycles through 361 frequency points between 1,370 and 1,730 Hz rather than holding one.
It supports the principle. It does not support a number, a timeline, or an outcome.
What it cannot support
It was not a facial study. Facial muscles are thin, small, and many attach into the SMAS rather than to bone at both ends, so transfer from a limb protocol has to be argued rather than assumed.
It was not a study of any consumer device, ours included. Our specific frequency sequence is an implementation of the principle, not a tested version of it.
It measured a performance endpoint rather than appearance. Nothing in it speaks to wrinkles, jawline contour, or how anyone's face looks after twelve weeks.
And it does not establish that accommodation is prevented. Delayed and prevented are different claims and only the first is supported.
The paper that found otherwise
Papaiordanidou and colleagues report a case in which frequency modulation did not deliver the expected benefit (10.1371/journal.pone.0084740).
That is not a refutation of Downey; different protocols, muscles and endpoints produce different results, and a small literature with mixed findings is a normal state for a question like this.
It does mean that anybody presenting modulation as settled is overstating it, and that a brand citing only the supportive paper is choosing its evidence rather than presenting it.
We cite both because the second one exists.
Why this page exists
Most brands in this category reference frequency variation and very few name the study, which makes the claim unfalsifiable by design.
Naming it lets you check it, and checking it is how you find out that it supports a design principle rather than a result.
Maffiuletti's work adds a caution from the same field: a dial setting is not the same as the tension actually produced in the muscle (PMID 29233625), which is worth holding on to whenever anyone compares two devices by their level numbers.
What the facial evidence is, separately
Kavanagh and colleagues followed 108 women through 12 weeks of motor-level facial stimulation and measured an 18.6 percent increase in cheek muscle thickness (10.1111/jocd.12007). Chang and colleagues ran a double-blind sham-controlled trial (10.3390/ijerph17113783), and Kwak and colleagues used a split-face design (10.52660/jksc.2023.29.6.1505).
Those are the papers that speak to faces, and they are still category evidence rather than trials of a consumer device.
Downey is about how a device should be built. Kavanagh is about what the category of stimulation can do. Neither is about what a particular product will do to you, and keeping those three separate is the honest way to read all of it.
For the mechanism, see accommodation, and for judging studies generally, how to read a facial device study.